VEGFA and wet macular degeneration: Current therapeutic strategies for wet AMD primarily aim to reduce oxidative stress through antioxidants and to limit pathological neovascularization by inhibiting vascular endothelial growth factor (VEGF) release and expression with anti-VEGF compounds [88].